Engineered with precision dynamic airflow, digital multi-point dosimetry, and intelligent concentration monitoring for preclinical inhalation toxicology in South Korea.
Analyzing the intersection of rigorous chemical regulations, high-tech biopharma research clusters, and ambient fine particulate safety evaluation in the Republic of Korea.
The South Korean preclinical research and chemical safety assessment market has experienced unprecedented modernization over the past decade. Driven by rigorous regulatory frameworks such as K-REACH (Act on Registration and Evaluation of Chemicals), the Chemical Control Act (CCA), and the continuous elevation of standard operating procedures by the Ministry of Food and Drug Safety (MFDS), South Korean contract research organizations (CROs), university institutes, and multinational pharmaceutical enterprises are expanding their inhalation toxicology infrastructures.
Inhalation exposure systems represent the technological pinnacle of preclinical toxicology. Unlike traditional oral gavage or intravenous administration routes, respiratory exposure requires continuous dynamic stabilization of aerosolized particles, precise aerodynamic particle size distribution (APSD), and real-time dosimetry. In South Korea's vibrant bio-hubs—including the Songdo Bio Cluster (Incheon), Osong Bio Valley (Chungcheongbuk-do), and the Daegu-Gyeongbuk Medical Innovation Complex—researchers are actively seeking automated, intelligent exposure systems that minimize cross-contamination and guarantee exact OECD Guideline compliance.
South Korea requires comprehensive safety dossiers for industrial chemicals imported or manufactured over designated tonnage thresholds. Automated dynamic inhalation chambers ensure reproducible 28-day and 90-day sub-chronic inhalation studies under Good Laboratory Practice (GLP) conditions.
Due to East Asian transboundary dust (Yellow Dust / Hwangsa) and localized urban diesel emissions, South Korean academic centers lead extensive research on PM2.5 and PM10 pulmonary pathology using online enriched rodent whole-body exposure chambers.
With major Korean pharmaceutical innovators developing dry powder inhalers (DPI), nebulized biologic delivery, and mRNA-based pulmonary therapeutics, high-precision nose-only exposure systems provide targeted alveolar deposition data with zero systemic interference.
A specialized National "Little Giant" enterprise dedicated to the R&D, design, and manufacturing of state-of-the-art aerosol and inhalation toxicology instrumentation.
Beijing Huironghe Technology Co., Ltd. (overseas brand "HRHINS"), founded in 2010 with a registered capital of 10 million yuan, is located in the Beijing Economic-Technological Development Area. The company specializes in the R&D, production, sales, and technical services for inhalation toxicity, genetic toxicity, inhaler testing, aerosol detection, and lab automation systems.
HRHINS has been recognized as a National High-tech Enterprise and designated as a Beijing Municipal Corporate Science and Technology R&D Institution. Additionally, it has received honors such as being a Beijing "Specialized, Refined, Unique, and Innovative" SME, a China Manufacturing Champion Enterprise, and a Beijing Intellectual Property Demonstration Enterprise.
Further accolades include being named a National Intellectual Property Advantage Enterprise in 2019, a National "Little Giant" SME (the first in the aerosol scientific instrument field) in 2022, and a recipient of the Second Prize in Scientific and Technological Progress from the Tianjin Municipal Government in 2022. The company occupies over 3,000 sqm of modern offices, a cleanroom assembly R&D center, and precision machining workshops.
HRHINS has developed over 60 innovative instruments, including aerosol generators, inhalation systems, fully automated QuEChERS system, multi-stage cascade impactor, and breathing simulator, etc.
The aerosol toxicity instrument line offers a complete suite for studies involving rats, mice, guinea pigs, ferrets, rabbits, dogs, and monkeys. Supported exposure methods are equally comprehensive, covering nose-head, whole-body, airborne infection, and in vitro cell culture exposures.
Crucially, all products—from aerosol generation and detection to sampling and system control—are based on independent intellectual property. These solutions are widely employed by GLP laboratories, safety assessment centers, universities, research institutions, and hospital respiratory departments worldwide.
HRHINS holds certifications for the ISO 9001:2015 Quality Management System, ISO 14001:2015 Environmental Management System, ISO 45001:2018 Occupational Health and Safety Management System, and GB/T 29490-2013 Intellectual Property Management System.
In 2018, HRHINS supported the establishment of the Respiratory Toxicology Committee of the Chinese Society of Toxicology and became its founding sponsor. The company also gained council membership in the Chinese Society of Toxicology, the Chinese Environmental Mutagen Society, and the Zhongguancun New Bio-pharmaceutical Industry Alliance.
How cutting-edge exposure chambers empower South Korean researchers in chemical risk evaluation, biosafety containment, and in vitro alternative testing.
In alignment with South Korea's landmark ban on animal testing for cosmetics and the expanding adoption of OECD Test Guidelines for Alternative Methods, researchers in Gyeonggi-do and Seoul are transitioning toward in vitro cell exposure. The Multi-concentration Cell Culture System delivers aerosolized compounds directly onto human lung epithelial cells cultured at the air-liquid interface, simulating human lung physiology without animal sacrifice.
Following historical public health emergencies (such as MERS-CoV and COVID-19), South Korean national laboratories and research foundations have heavily invested in high-level biosafety facilities. The Biosafety Nose-only Exposure System utilizes dual HEPA negative-pressure sealed cabinets, emergency fail-safe valves, and automated fumigation cycles to safely evaluate airborne infectious agents, therapeutic vaccines, and aerosol countermeasure drugs.
In environmental, agricultural, and biological matrices analysis throughout Korean testing institutes (such as the National Institute of Environmental Research - NIER), sample throughput is a major bottleneck. The Fully Automated QuEChERS System optimizes liquid handling, salt addition, vortexing, and centrifugation for high-accuracy residue screening in compliance with Korean Food Code standards.
Full suite of advanced inhalation toxicity, aerosol generation, in vitro exposure, and automated analytical platforms available for South Korean laboratories.
Ensuring compliance with international OECD guidelines and national South Korean GLP assessment criteria.
In preclinical inhalation toxicology, data credibility depends on total chamber uniformity and rigorous environmental stability. HRHINS inhalation exposure systems are engineered to exceed the rigorous benchmarks established by the OECD Test Guidelines (TG 403, 412, 413, and 436) as well as the US EPA Health Effects Test Guidelines and South Korean MFDS regulations. Each exposure module is equipped with smart closed-loop aerosol feedback systems that integrate real-time optical particle counters, multi-wavelength photometers, and cascade impactors for continuous Mass Median Aerodynamic Diameter (MMAD) and Geometric Standard Deviation (GSD) verification.
Whether configuring automated solid dust feed generators for nanoscale particulate toxicology, ultrasonic and vibrating mesh nebulizers for delicate protein solutions, or specialized vapor generators for volatile organic solvents, HRHINS delivers turnkey engineering from chamber modeling to data logging software with full 21 CFR Part 11 compliance capability. With proven implementations in world-class research hubs, HRHINS stands as a trusted manufacturing partner for South Korea's bio-pharmaceutical and chemical safety industries.